Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, Schwarz A, Kammers K, Erhardt A, Scherer A, Bölke E, Schauer M.: Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res. 2011 Oct 10;16(10):451-6.

­­

C. Matuschek, H. B. Prisack, E. Boelke, W. Budach, M. Peiper, M. Rezai, H. Bojar; University of Duesseldorf, Duesseldorf, Germany; European Institute for Molecular Pathology, Duesseldorf, Germany; Breast Center Düsseldorf Luisenhospital, Düsseldorf, Germany: Microarray-based gene expression profiles reliably predict ELISA-derived uPA and PAI-1 levels in breast cancer biopsies. A comparison between fresh frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) samples. ASCO 2011,June 3-7;  Permanent Abstract ID 10555

Matuschek C, Bölke E, Lammering G, Gerber PA, Peiper M, Budach W, Taskin H, Prisack HB, Schieren G, Orth K, Bojar H.: Methylated APC and GSTP1 Genes in Serum DNA Correlate with the Presence of Circulating Blood Tumor Cells and are Associated with a More Aggressive and Advanced Breast Cancer Disease. Eur J Med Res. 2010 Jul 26;15(7):277-86.PMID: 20696638

Roth SL, Audretsch W, Bojar H, Lang I, Willers R, Budach W.: Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol. 2010 Jun;186(6):299-306. Epub 2010 May 21.PMID: 20495968

Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.: ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010 Apr 15;16(8):2391-401. Epub 2010 Apr 6.PMID: 20371687

Winzer KJ, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, Schumacher M; German Breast Cancer Study Group (GBSG): Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2010 Jan;46(1):95-101. Epub .PMID: 19879131

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.: Gene expression of circulating tumour cells in breast cancer patients. Eur J Med Res. 2009 Sep 28;14(10):426-32.PMID: 19748849

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.: Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients. Eur J Med Res. 2009 Aug 12;14(8):359-63.PMID:

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group: Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. Epub 2008 Oct 25.PMID: 18953651 [PubMed - indexed for MEDLINE]Related citations

Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, Bojar H, Tannapfel A, Hengge UR.: ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol. 2007 Sep;127(9):2207-15. Epub 2007 May 17.PMID: 17508026

Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO: Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007 May 15;109(10):2016-24.PMID: 17394193

Modlich O, Bojar H: Can a 70-gene signature provide useful prognostic information in patients with node-negative breast cancer? Nat Clin Pract Oncol. 2007 Apr;4(4):216-7. Epub 2007 Feb 6. No abstract available. PMID: 17290242

Domagk D, Schaefer KL, Eisenacher M, Braun Y, Wai DH, Schleicher C, Diallo-Danebrock R, Bojar H, Roeder G, Gabbert HE, Domschke W, Poremba C.: Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci. Oncol Rep. 2007 Feb;17(2):399-407.PMID: 17203180

Modlich O, Prisack HB, Bojar H.: Breast cancer expression profiling: the impact of microarray testing on clinical decision making. Expert Opin Pharmacother. 2006 Oct;7(15):2069-78. Review.PMID: 17020433

Weis-Müller BT, Modlich O, Drobinskaya I, Unay D, Huber R, Bojar H, Schipke JD, Feindt P, Gams E, Müller W, Goecke T, Sandmann W.: Gene expression in acute Stanford type A dissection: a comparative microarray study. J Transl Med. 2006 Jul 6;4:29.PMID: 16824202 [PubMed]Free PMC ArticleFree textRelated citations

Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, Tannapfel A, Bojar H, Ruzicka T, Hengge UR: STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol. 2006 Oct;126(10):2272-80. Epub 2006 Jun 1.PMID: 16741510

Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H: Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy. Anticancer Res. 2005 Nov-Dec;25(6C):4615-21.PMID: 16334152

Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H: Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med. 2005 Aug 9;3:32.PMID: 16091131

Liebau C, Roesel C, Schmidt S, Karreman C, Prisack JB, Bojar H, Merk H, Wolfram N, Baltzer AW: Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. Anticancer Res. 2004 Sep-Oct;24(5A):2861-7.PMID: 15517889

Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H: Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res. 2004 Oct 1;10(19):6418-31.PMID: 15475428

Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO: Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res. 2004 May 15;10(10):3410-21.PMID: 15161696

Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, Haas R, Kronenwett R.: Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector. Cancer Gene Ther. 2003 Dec;10(12):898-906.PMID: 14712316

Liebau C, Merk H, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Baltzer AW.: Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol Ther. 2002;7(4):135-42.PMID: 14660053

Liebau C, Merk H, Roesel C, Schmidt S, Karreman C, Prisack JB, Bojar H, Baltzer AW.: rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid: a new option as immuno-therapy for osteosarcoma? Anticancer Res. 2002 Sep-Oct;22(5):2559-65.PMID: 12529964

Balz V, Prisack HB, Bier H, Bojar H.: Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. Cancer Genet Cytogenet. 2002 Oct 15;138(2):120-7.PMID: 12505256

Müller BT, Modlich O, Prisack HB, Bojar H, Schipke JD, Goecke T, Feindt P, Petzold T, Gams E, Müller W, Hort W, Sandmann W.: Gene expression profiles in the acutely dissected human aorta. Eur J Vasc Endovasc Surg. 2002 Oct;24(4):356-64.PMID: 12323180

Hartmann KA, Modlich O, Prisack HB, Gerlach B, Bojar H.: Gene expression profiling of advanced head and neck squamous cell carcinomas and two squamous cell carcinoma cell lines under radio/chemotherapy using cDNA arrays. Radiother Oncol. 2002 Jun;63(3):309-20.PMID: 12142095

Hoffmann TK, Bojar H, Eckel J, van Lierop A, Balz V, Friebe-Hoffmann U, Hauser U, Bier H.: Effects of tamoxifen on human squamous cell carcinoma lines of the head and neck. Anticancer Drugs. 2002 Jun;13(5):521-31.PMID: 12045464

Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Merk H.: Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res. 2002 Mar-Apr;22(2A):931-6.PMID: 12014674

Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R.: Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood. 2002 Mar 15;99(6):2037-44.PMID: 11877277

Floeth FW, Shand N, Bojar H, Prisack HB, Felsberg J, Neuen-Jacob E, Aulich A, Burger KJ, Bock WJ, Weber F.: Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther. 2001 Nov;8(11):843-51.PMID:

Keil O, Bojar H, Prisack HB, Dall P.: Novel lipophilic chloroquine analogues for a highly efficient gene transfer into gynecological tumors. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2611-3.PMID: 11551761

Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M; German Breast Cancer Study Group.: Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001 Jun;37(9):1123-31.PMID: 11378343

Struse K, Audretsch W, Rezai M, Pott G, Bojar H.: The Estrogen Receptor Paradox in Breast Cancer: Association of High Receptor Concentrations with Reduced Overall Survival. Breast J. 2000 Mar;6(2):115-125.PMID: 11348346

Schmoor C, Bastert G, Dunst J, Bojar H, Christmann D, Unbehaun V, Tümmers G, Bauer W, Sauerbrei W, Schumacher M. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group. Int J Cancer. 2000 May 1;86(3):408-15.PMID: 10760830

Sauerbrei W, Bastert G, Bojar H, Beyerle C, Neumann RL, Schmoor C, Schumacher M.:Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. German Breast Cancer Study Group. J Clin Oncol. 2000 Jan;18(1):94-101.PMID: 10623698